Per-Erik Persson
Plus aucun poste en cours
Profil
Per-Erik Persson was appointed to the board of directors in November 2003.
Mr. Persson serves as a member of the compensation committee.
Prior to his retirement in 1996, Mr. Persson had served since 1993 as Director of Seeds Division and Member of the Group Management of Sandoz AG and President and CEO of Sandoz Seeds Ltd., Switzerland.
From 1975 through 1993, Mr. Persson served in several managerial positions with Hilleshog AG including Managing Director and CEO of Hilleshog AB and President Director General of Hilleshog NK, France.
Mr. Persson also serves as a director of Viragen International.
Anciens postes connus de Per-Erik Persson
| Sociétés | Poste | Fin |
|---|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Directeur/Membre du Conseil | 08/09/2008 |
Viragen International, Inc.
 Viragen International, Inc. BiotechnologyHealth Technology The Group's principal activities are to research, develop, manufacture and market a natural human alpha interferon product indicated for treatment of a broad range of viral and malignant diseases. The Group produces a natural human alpha interferon product under the tradename of MultiferonTMfrom human white blood cells, also known as leukocytes. Natural interferon-alpha is one of the body's most important natural defense mechanisms to foreign substances like viruses, but it also stimulates and modulates the human immune system. In addition, interferon inhibits the growth of various viruses including those associated with diseases like hepatitis, some types of cancer, multiple sclerosis, and severe acute respiratory syndrome (SARS). | Directeur/Membre du Conseil | 30/06/2005 |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Viragen International, Inc.
Viragen International, Inc. BiotechnologyHealth Technology The Group's principal activities are to research, develop, manufacture and market a natural human alpha interferon product indicated for treatment of a broad range of viral and malignant diseases. The Group produces a natural human alpha interferon product under the tradename of MultiferonTMfrom human white blood cells, also known as leukocytes. Natural interferon-alpha is one of the body's most important natural defense mechanisms to foreign substances like viruses, but it also stimulates and modulates the human immune system. In addition, interferon inhibits the growth of various viruses including those associated with diseases like hepatitis, some types of cancer, multiple sclerosis, and severe acute respiratory syndrome (SARS). | Health Technology |
Viragen, Inc.
Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
